Cynomolgus monkey only (rabbit used for efficacy and PK/PD)
“The rabbit was selected as efficacy species, the Cynomolgus monkey was selected as the nonrodent safety species and both species were used in pharmacokinetic/pharmacodynamic (PK/PD) assessment.”
Sub-nanomolar TFPI binding with similar constants in rabbit, monkey and human (KD 0.22, 0.06, 0.04 nM)
“Characterisation of concizumab binding to TFPI showed high affinity, sub-nanomolar binding to rabbit, NHP and human TFPI with similar binding constants (KD of 0.22 nM, 0.06 nM and 0.04 nM for rabbit, Cynomolgus monkey and human, respectively).”